Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While KPV is investigated as an anti-inflammatory and barrier-protective agent in skin and mucosal models, reducing pro-inflammatory cytokines and promoting tissue repair684, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While KPV works as the C-terminal Lys-Pro-Val tripeptide fragment of α-MSH, which exerts potent anti-inflammatory effects largely via inhibition of NF-κB signaling and modulation of cytokine expression, with many actions independent of classical melanocortin receptor activation684, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
KPV
POMC
Semaglutide
GCG
KPV and Semaglutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: KPV is more often discussed in the realm of Immunology and inflammation, Gastroenterology, and Dermatology and aesthetics, whereas Semaglutide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. They also influence different molecular systems, with KPV tracking more closely to Melanocortin receptor while Semaglutide centers more on GLP-1 receptor. KPV has a more natural endogenous origin, while Semaglutide is closer to synthetic analog background and their development context also differs, with KPV in Preclinical development while Semaglutide is approved. KPV takes the form of a linear peptide, whereas Semaglutide is closer to a peptide conjugate, Semaglutide incorporates lipidation features that are not part of KPV; while their sequence patterns also diverge, with KPV showing protein-mimetic sequence features and Semaglutide showing alpha-helical domain features.